ResearcherHarvard UniversityNo recent work listed

Mahmoud Lotfi Nasr

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0712-8667; OpenAlex author ID A5071053872. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper

Papers 1

Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. Last author DOI 10.1016/j.drudis.2022.103434 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Cristina R. Ferrone · 1 shared paper, 2023 · strength 0.26
- Paper Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. DOI 10.1016/j.drudis.2022.103434 ↗
Ahmed O. Elzoghby · 1 shared paper, 2023 · strength 0.26
- Paper Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. DOI 10.1016/j.drudis.2022.103434 ↗
Soldano Ferrone · 1 shared paper, 2023 · strength 0.26
- Paper Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. DOI 10.1016/j.drudis.2022.103434 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.